The Role of High Sensitivity Troponin: More Acute Coronary Syndromes  or More False Positive Results? by Gavrielatos, Gerasimos
The Role of High Sensitivity Troponin: 
More Acute Coronary Syndromes  
or More False Positive Results?
Gerasimos Gavrielatos, MD
A B S T R A C T
Cardiac troponins (cTn) are the most sensitive and specific biomarkers of myocardial 
damage. Troponin has both diagnostic and prognostic significance for acute coro-
nary syndrome (ACS). The joint European Society of Cardiology/American College 
of Cardiology Foundation/American Heart Association/World Heart Federation 
task force recommendations for a universal definition of acute myocardial infarc-
tion (AMI) in 2007 are based on detection of cTn and associated clinical evidence. 
Although the clinical introduction of new generation high sensitivity cTnT and cTnI 
assays is certainly valuable in the appropriate setting, its widespread use in a variety 
of clinical situations may lead to the detection of cTn elevation in absence of throm-
botic ACS. Until now there is no clarity between “sensitive” and “high sensitive” cTn 
assays something that raises concerns regarding the interpretation of the latest clini-
cal studies. The increased analytical sensitivity against compromised specifity may 
increase ‘‘false positive’’ results in patients with cardiovascular disease or apparently 
healthy subjects with previously undetected cTn levels. A cTn rise in the absence of 
ACS should prompt for an assessment for a different, non-ischemic mechanism of 
troponin elevation and direct management at the primary cause. The role of the clini-
cian is to apply clinical doubts where abnormal cTn levels are not due to myocardial 
injury. The current strategy of management of such patients is based on established 
algorithms and clinical knowledge.
Cardiac troponins I (cTnI) and T (cTnT) have been documented as the preferred 
biomarkers for the recognition of myocardial damage, in the diagnosis of myocardial 
infarction and risk stratification of patients presenting with symptoms of acute coro-
nary syndrome (ACS).1 The recently released guidelines from the European Society 
of Cardiology (ESC) emphasized again the use of the 99th-percentile value derived 
from a reference population as the clinical-decision threshold, using an assay with 
an imprecision (coefficient of variation, CV) of ≤10% at the upper reference limit 
(URL).2 Thus, only one in a hundred healthy people will have a result above this and 
even then it will not be more than a few units higher. Until recently however, there 
was no clinically available assay capable of consistently achieving this recommended 
precision. Additionally, since the troponin concentration cut off is influenced by the 
analytic precision and sensitivity of the assay and diverse troponin assays have diverse 
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performance features, interpretation of troponin results often 
varies among institutions.3,4
The continuously improved analytic performance of 
troponin tests has led to the advent of “sensitive” and “high 
sensitive” troponin assays. Although there is no consensus 
regarding the definition of an hs-cTn assay it has two differ-
entiating features from contemporary cTn assays: 1) detection 
of cTn in healthy persons and 2) a precise definition of what 
is “normal” (= the 99th percentile).5 Its unique ability is to 
measure troponin concentrations in populations with previ-
ously undetectable levels. For example, the 99th percentile 
value for the first-generation troponin T assay was 0.06 μg/L, 
which was reduced to 0.01 μg/L by the fourth-generation assays. 
6 Now the fifth generation high sensitivity troponin assay can 
measure troponin concentrations approximately 10-fold lower 
than conventional assays, and as a result, the 99th percentile 
concentration continues to decrease.7 Although criteria are 
not established at this time, some suggested characteristics 
might be:
 1. Capability to generate credible measurements for most 
samples (>80%) of a normal reference population.
 2. The required cTn quantity relevant to a CV of the total 
error of <10% is significantly lower than the 99th percentile 
of the normal reference population.8
A classification based on the analytical imprecision at 
the 99th and the % of reference subjects showing detect-
able values has been proposed. This schema suggests that 
immunoassays should be classified as guideline acceptable if 
inaccuracy is <10%, clinically usable if it is between 10%-20% 
and non-acceptable if >20%. Depending on their analytical 
sensitivity and imprecision characteristics, contemporary and 
high-sensitivity cardiac troponin assays are classified into one 
of 4 categories: <50%, 50%-75%, 75%-95%, and >95%.9 At 
the present time, there are 23 cardiac troponin assays available 
(21 for cTnI, 2 for cTnT) from 14 manufacturers.10 According 
to the above mentioned characteristics, none of the current 
cTn methods could be denominated as high-sensitive. 9 This 
raises some serious concerns since a clinical study that uses 
cardiac troponin cannot be comprehended from a reader in 
terms of content, value, impact and generalizability, without 
identifying the exact cardiac troponin immunoassay used and 
its performance characteristics.10 Additionally the implementa-
tion of a credible meta-analysis for the assessment of cardiac 
troponin utilization cannot be conducted if the particular 
troponin assay used in each study included is unknown. This is 
an acceptable method to ensure that only data from equivalent 
troponin assays are shared.
A recently published study determined that lowering the 
diagnostic threshold of cTn for diagnosis of acute myocardial 
infarction (AMI) could reduce morbidity and mortality. How-
ever, the biggest challenge of lowering the diagnostic threshold 
of cTn for AMI would be a greater number of patients with 
elevated cTn, including those due to non-ACS thrombotic 
causes.11 A range of sometimes unknown mechanisms can 
cause non-thrombotic myocardial tissue injury and a rise of 
cardiac troponin and an excess of non-coronary situations 
can also lead to troponin elevation, but they usually do not 
follow the characteristic escalation pattern of an AMI and 
the accompanying clinical, ECG and imaging standards.12 In 
other words, increased cTnI or cTnT values alone are unable 
to indicate the pathophysiological mechanism underlying the 
detected myocardial damage, which may be unrelated to is-
chemia. Therefore, an increased marker value, without clinical 
indication of myocardial ischemia, should prompt for a search 
for other causes of cardiac damage (Table 1).
Amongst others, the anticipated causes for non-ACS 
cTn elevation comprise autonomic nervous system disorders, 
with subsequent excess of sympathetic activity and increased 
catecholamine effect on myocardial cells;13 straight myocardial-
cell damage by traumatic or inflammatory development; vol-
ume and pressure overload, causing an extreme intensification 
in wall tension with secondary myofibrillary damage;14 and 
reduced renal excretion.15 Occasionally the result of inflamma-
tory cytokines or oxidative stress, myocardial hibernation, or 
apoptosis might be elevated cTn. Another important issue is 
assay interference with heterophilic antibodies which through 
hemolysis can lead to false- positive troponin elevations.12 It is 
estimated that heterophilic antibodies cause about one false 
result in every 2000 investigations with modern immunoas-
says.16 To minimize the occurrence of false-positive troponins, 
non-specific blocking antibodies have been added to modern 
assays to reduce interference with the results.
Recently, Eggers et al reported a ~7% of misclassified with 
AMI diagnosis (i.e., false positivity rate) troponin-positive pa-
tients with preexisting ST-T segment abnormalities, admitted 
for non-ACS chest pain or other symptoms indicative of myo-
cardial ischemia.17 Accordingly, several studies have validated 
that hs-cTn assays increased the number and promptness of 
ACS diagnosis, but also increased the amount of false posi-
tives, that is, non-ACS-related origin.18,19 Hence, with hs-cTn 
assays, even the healthiest of people will demonstrate meas-
urable troponin concentrations, and this has a direct effect 
on the application and interpretation of the 99th percentile 
as a cutoff. Although studies using this cutoff for myocardial 
infarction with hs-cTn have demonstrated excellent sensitiv-
ity compared with conventional cTn assays, the diagnostic 
specificity for AMI20 has decreased, with the prevalence of 
positive results nearly doubled in the emergency room setting. 
For instance, Kavsak et al have indicated that it is unclear, 
when using hs-cTn assays, whether the 99th percentile cut-off 
derived from a younger/healthy population is appropriate for 
the stated use according to the universal definition of AMI, or 
an aged matched population would be the most appropriate.21 
Similarly Potter et al have found a transient troponin rise in 
apparently healthy young children assessed on 3 separate oc-
casions with hs-TnT assays more due to an infective etiology 
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than of cardiac origin.22
The utilization in clinical practice of the new highly sensi-
tive troponin assays is a trade-off and, it is unclear if they will 
lead to increased clarity or more confusion for most physi-
cians.23 Existing data clearly suggest that they will allow earlier 
diagnosis of AMI (within 1–2 hours after thoracic pain onset), 
as well as recognition of very small (focal) areas of myocardial 
necrosis, without avoiding also the detection of non-ischemic 
causes of cardiomyocyte necrosis related to various diseases, 
which challenges the clinician to differentiate them (Table 
2).4 It is stated that the larger the rise in high-sensitivity cTn 
within the first few hours in the emergency department, the 
higher the probability that it is AMI.5
Serial changes documented by a second sample earlier 
than previously recommended, e.g. after 2 hours rather than 
after 6 hours, accelerate the diagnostic process and help to 
differentiate acute cardiac disorders (showing a rise and/or 
fall) from chronic cardiac disease which usually exhibit con-
stant cTn levels.25 It is a matter of debate whether absolute 
or relative changes best separate acute from chronic cTn 
elevations, as well as AMI from other causes of cTn elevation 
even if preliminary data suggest that an absolute change in 
hs-cTn level appears to improve diagnostic performance.25 For 
emergency room physicians faced with disposition decisions, 
the question is not so much about whether the patient expe-
rienced an acute myocardial infarction but rather what their 
risk of a pending cardiovascular episode is. Earlier decision 
making should result in earlier treatment or to earlier triage 
to an invasive strategy, whereas a repeated normal level at an 
earlier time point than currently recommended may lead to 
TABLE 2. Recommended Protocol for Troponin Testing 
Using High Sensitivity Assays in “Ruling-Out” Acute 
Coronary Syndrome (ACS)
All patients with a suspected ACS should undergo troponin testing 
on arrival at ED to ‘rule in’ ACS within the differential diagnosis
For a patient with a positive troponin result or a change in troponin 
levels over time, neither ACS nor other significant pathology (e.g. 
pulmonary embolus, aortic dissection, and sepsis) can be excluded. 
These patients are at higher risk of subsequent events. A positive 
result should be considered within the entire clinical context 
(history, examination, ECG findings and other investigations). 
Further investigations directed at all plausible clinical diagnoses 
should be considered and, if ACS is thought to be the likely cause, 
these patients may require cardiology assessment.
All patients with a negative result should undergo repeat testing 
3–4 hours later.
The testing interval to ‘rule out’ MI may be reduced to 3 hours, 
provided that one sample is taken at least 6 hours after symptom 
onset.
Patients with a negative result at 3 hours after presentation and 
at least 6 hours after the onset of pain should be considered for 
early assessment by non-invasive anatomic or functional testing, 
as determined by local availability.
For patients presenting more than 6 hours after pain onset, a single 
high sensitivity troponin assay is sufficient to rule out myocardial 
infarction in the absence of on-going chest pain.
ECG = electrocardiogram; ED = emergency department; MI = 
myocardial infarction
TABLE 1. Acute Troponin Elevation in Non-Thrombotic 
Situations
Trauma (including contusion, ablation, pacing, implantable de-
fibrillator firings, cardioversion, cardiac biopsy, cardiac surgery)
Acute and chronic congestive heart failure 
Aortic valve disease, hypertrophic, obstructive cardiomyopathy 
with left ventricular hypertrophy 
Hypertension- Hypotension with arrhythmias 
Tachyarrhythmias
Postoperative non-cardiac surgery 
Renal failure
Critical illness – especially diabetes, respiratory failure, GI bleed-
ing, sepsis 
Drug toxicity (adriamycin, 5-Fluorouracil, herceptin, snake en-
venomation, carbon monoxide poisoning) 
Hypothyroidism 
Abnormalities in coronary vasomotion – including coronary va-
sospasm 
Apical ballooning 
Inflammatory disease – myocarditis, parvovirus B19, Kawasaki 
Disease, sarcoid, myocardial involvement in bacterial endocarditis 
Uncomplicated percutaneous coronary intervention (PCI) 
Pulmonary embolism, pulmonary hypertension 
Sepsis 
Burns – particularly when surface area >30% 
Infiltrative disease affecting myocardium – amyloidosis, hemo-
chromatosis, sarcoid, scleroderma 
Acute neurological disease – e.g. stroke, subarachnoid hemor-
rhage 




HOSPITAL CHRONICLES 2010, VOLUME 7, SUPPLEMENT 1: «ATHENS CARDIOLOGY UPDATE 2012»
earlier discharge of patients with the consequent improvement 
of health outcomes and profound cost savings on the care of 
suspected ACS patients.
In conclusion, there is evidence that it is problematic to 
reliably diagnose ACS in patients with suspicious chest pain 
syndrome based only on one sample measurement of cTnI or 
cTnT due to the relatively low specificity of existing cardiac 
troponin assays for ischemic myocardial injury.26 Clinical 
judgment and ECG findings integrated into algorithms with 
the inclusion of hs-cTn have been proposed to be useful tools 
for the management of patients admitted to an emergency 
department with suspected ACS.12 The new generation of high 
sensitivity troponin assays can better define the true normal 
levels and the 99th URL, facilitating better risk stratification of 
patients who do not have increased troponin by current assays 
and may allow risk stratification of patients with chronic stable 
angina and patients with heart failure.28 Research progress and 
development has led to the advent of a multimarker approach 
for the diagnosis of ACS based on the combination of selected 
biomarkers which seems to add incremental predictive value 
to further risk stratification in an otherwise seemingly homo-
geneous non-ST elevation ACS population.29 All these data 
pave the way for adaptation of treatment options that can offer 
benefit to patients recognized to be at increased risk, which 
will eventually improve patient outcome.
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